Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, Apellis Pharmaceuticals Inc’s stock clocked out at $47.64, up 0.23% from its previous closing price of $47.53. In other words, the price has increased by $0.23 from its previous closing price. On the day, 0.69 million shares were traded. APLS stock price reached its highest trading level at $48.42 during the session, while it also had its lowest trading level at $46.63.
Ratios:
To gain a deeper understanding of APLS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.50 and its Current Ratio is at 3.10. In the meantime, Its Debt-to-Equity ratio is 0.57 whereas as Long-Term Debt/Eq ratio is at 0.54.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on February 05, 2024, Upgraded its rating to Buy and sets its target price to $80 from $68 previously.
On November 09, 2023, Goldman started tracking the stock assigning a Buy rating and target price of $74.Goldman initiated its Buy rating on November 09, 2023, with a $74 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 08 ’24 when Deschatelets Pascal sold 69,107 shares for $54.17 per share. The transaction valued at 3,743,605 led to the insider holds 1,115,983 shares of the business.
Sullivan Timothy Eugene sold 4,000 shares of APLS for $234,640 on Apr 01 ’24. The Chief Financial Officer now owns 93,338 shares after completing the transaction at $58.66 per share. On Mar 19 ’24, another insider, Dunlop A. Sinclair, who serves as the Director of the company, sold 18,681 shares for $57.18 each. As a result, the insider received 1,068,161 and left with 173,998 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, APLS now has a Market Capitalization of 5744526336 and an Enterprise Value of 5499903488. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.48 while its Price-to-Book (P/B) ratio in mrq is 29.28. Its current Enterprise Value per Revenue stands at 13.868 whereas that against EBITDA is -10.672.
Stock Price History:
The Beta on a monthly basis for APLS is 0.96, which has changed by -0.4551069 over the last 52 weeks, in comparison to a change of 0.23061275 over the same period for the S&P500. Over the past 52 weeks, APLS has reached a high of $94.75, while it has fallen to a 52-week low of $19.83. The 50-Day Moving Average of the stock is -20.45%, while the 200-Day Moving Average is calculated to be -9.07%.
Shares Statistics:
It appears that APLS traded 1.36M shares on average per day over the past three months and 1389850 shares per day over the past ten days. A total of 119.56M shares are outstanding, with a floating share count of 98.84M. Insiders hold about 18.03% of the company’s shares, while institutions hold 91.88% stake in the company. Shares short for APLS as of 1711584000 were 10439851 with a Short Ratio of 7.69, compared to 1709164800 on 10064166. Therefore, it implies a Short% of Shares Outstanding of 10439851 and a Short% of Float of 10.05.
Earnings Estimates
The dynamic stock of Apellis Pharmaceuticals Inc (APLS) is currently attracting attention from 12 analysts actively involved in rating its market status.On average, analysts expect EPS of $-0.54 for the current quarter, with a high estimate of $-0.28 and a low estimate of $-0.83, while EPS last year was $-1.56. The consensus estimate for the next quarter is $-0.37, with high estimates of $0.09 and low estimates of $-0.6.
Analysts are recommending an EPS of between $0.46 and $-2.18 for the fiscal current year, implying an average EPS of $-1.23. EPS for the following year is $1.2, with 11 analysts recommending between $2.28 and $0.13.
Revenue Estimates
In the current quarter, 14 analysts expect revenue to total $161.78M. It ranges from a high estimate of $178.58M to a low estimate of $137.45M. As of the current estimate, Apellis Pharmaceuticals Inc’s year-ago sales were $44.85M, an estimated increase of 260.70% from the year-ago figure. For the next quarter, 14 analysts are estimating revenue of $187.99M, an increase of 167.60% less than the figure of $260.70% in the same quarter last year. There is a high estimate of $228.28M for the next quarter, whereas the lowest estimate is $162.63M.
A total of 14 analysts have provided revenue estimates for APLS’s current fiscal year. The highest revenue estimate was $919.78M, while the lowest revenue estimate was $719.23M, resulting in an average revenue estimate of $795.83M. In the same quarter a year ago, actual revenue was $396.59M, up 100.70% from the average estimate. Based on 13 analysts’ estimates, the company’s revenue will be $1.18B in the next fiscal year. The high estimate is $1.57B and the low estimate is $936.9M. The average revenue growth estimate for next year is up 48.80% from the average revenue estimate for this year.
